• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多次口服给药后健康男性精液中来那度胺的分布。

Distribution of lenalidomide into semen of healthy men after multiple oral doses.

机构信息

Celgene Corporation, 86 Morris Avenue, Summit, NJ 07091, USA.

出版信息

J Clin Pharmacol. 2010 Jul;50(7):767-74. doi: 10.1177/0091270009355157. Epub 2010 Feb 16.

DOI:10.1177/0091270009355157
PMID:20160158
Abstract

Lenalidomide is a thalidomide analog and an immunomodulatory drug with demonstrated efficacy in various hematological malignancies. The distribution of lenalidomide into semen was evaluated in healthy subjects. Twenty-four male subjects were randomized into 4 equal groups for semen collection. All subjects received lenalidomide 25 mg once daily for 4 days. After the last dose, a single semen sample was collected from subjects, at approximately 2, 24, 72, and 168 hours for groups 1, 2, 3, and 4, respectively, and serial blood sampling was performed for 24 hours in all groups. The mean lenalidomide concentration in semen was 478 ng/mL at 2 hours and 10.0 ng/mL at 24 hours, which was higher than was the corresponding drug concentration in plasma (219 ng/mL at 2 hours and undetectable at 24 hours) but roughly paralleled the time course in plasma for drug elimination. The mean amount of lenalidomide was 1379 ng/ejaculate at 2 hours and 35 ng/ejaculate at 24 hours. The maximal drug content in a single ejaculate was <2000 ng (<0.01% of the daily 25-mg dose). Lenalidomide was undetectable in semen at 72 and 168 hours. Therefore, lenalidomide is essentially eliminated from seminal reservoirs by 72 hours postdose.

摘要

来那度胺是一种沙利度胺类似物,也是一种免疫调节剂,在多种血液系统恶性肿瘤中均显示出疗效。本研究评价了来那度胺在健康受试者精液中的分布情况。24 名男性受试者被随机分为 4 组,采集精液。所有受试者均接受来那度胺 25 mg,每日 1 次,连用 4 天。末次给药后,第 1、2、3 和 4 组受试者分别在约 2、24、72 和 168 小时采集单次精液样本,所有组均在 24 小时内进行连续采血。2 小时时,精液中平均来那度胺浓度为 478ng/ml,24 小时时为 10.0ng/ml,高于同期血浆中药物浓度(2 小时时为 219ng/ml,24 小时时无法检出),但与血浆中药物消除的时间过程大致平行。2 小时时,平均来那度胺排泄量为 1379ng/次射精,24 小时时为 35ng/次射精。单次射精中药物含量最高值<2000ng(<每日 25mg 剂量的 0.01%)。72 和 168 小时时,精液中无法检出来那度胺。因此,来那度胺在给药后 72 小时基本从精液贮库中消除。

相似文献

1
Distribution of lenalidomide into semen of healthy men after multiple oral doses.多次口服给药后健康男性精液中来那度胺的分布。
J Clin Pharmacol. 2010 Jul;50(7):767-74. doi: 10.1177/0091270009355157. Epub 2010 Feb 16.
2
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.来那度胺在不同程度肾功能损害受试者及血液透析受试者中的药代动力学。
J Clin Pharmacol. 2007 Dec;47(12):1466-75. doi: 10.1177/0091270007309563. Epub 2007 Oct 22.
3
Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.盐酸度洛西汀肠溶片在中国健康志愿者中的药代动力学:一项随机、开放标签、单剂量和多剂量研究。
Clin Ther. 2009 May;31(5):1022-36. doi: 10.1016/j.clinthera.2009.05.005.
4
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.免疫调节性沙利度胺类似物来那度胺的毒性特征:实体恶性肿瘤患者三种给药方案的I期临床试验
Eur J Cancer. 2006 Sep;42(14):2318-25. doi: 10.1016/j.ejca.2006.05.018. Epub 2006 Aug 8.
5
Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.五项 I 期、随机、双盲、平行研究中,健康成年志愿者单次和多次给药后 NXN-188 的安全性和药代动力学。
Clin Ther. 2010 Jan;32(1):146-60. doi: 10.1016/j.clinthera.2010.01.006.
6
Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.在健康男性受试者中单次口服[(14)C]-来那度胺后的药代动力学、代谢和排泄。
Cancer Chemother Pharmacol. 2012 Mar;69(3):789-97. doi: 10.1007/s00280-011-1760-3. Epub 2011 Oct 29.
7
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.来那度胺用于复发性原发性中枢神经系统肿瘤患者的I期试验。
Clin Cancer Res. 2007 Dec 1;13(23):7101-6. doi: 10.1158/1078-0432.CCR-07-1546.
8
Thalidomide is distributed into human semen after oral dosing.口服给药后,沙利度胺会分布到人体精液中。
Drug Metab Dispos. 2001 Oct;29(10):1355-7.
9
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.来那度胺单药治疗可使复发或难治性惰性非霍奇金淋巴瘤产生持久缓解。
J Clin Oncol. 2009 Nov 10;27(32):5404-9. doi: 10.1200/JCO.2008.21.1169. Epub 2009 Oct 5.
10
Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.在一项三阶段、开放标签、多剂量、单周期研究中,研究了依沙佐匹坦醋酸酯对健康受试者华法林稳态药代动力学和药效学的影响。
Clin Ther. 2010 Jan;32(1):179-92. doi: 10.1016/j.clinthera.2010.01.014.

引用本文的文献

1
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.健康志愿者参与免疫肿瘤学化合物早期临床试验的整合。
Front Oncol. 2022 Aug 29;12:954806. doi: 10.3389/fonc.2022.954806. eCollection 2022.
2
Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development.肿瘤药物研发中健康志愿者最佳部署的关键考量因素。
Clin Transl Sci. 2020 Jan;13(1):31-40. doi: 10.1111/cts.12703. Epub 2019 Oct 31.
3
Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma.
治疗非霍奇金淋巴瘤的临床药代动力学和药效学考虑因素。
Clin Pharmacokinet. 2020 Jan;59(1):7-23. doi: 10.1007/s40262-019-00807-8.
4
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.来那度胺/利妥昔单抗联合来那度胺维持治疗复发性中枢神经系统淋巴瘤的 1 期研究结果。
Blood Adv. 2018 Jul 10;2(13):1595-1607. doi: 10.1182/bloodadvances.2017014845.
5
Distribution of pomalidomide into semen of healthy male subjects after multiple doses.多次给药后泊马度胺在健康男性受试者精液中的分布。
Clin Pharmacol. 2018 May 7;10:53-62. doi: 10.2147/CPAA.S167017. eCollection 2018.
6
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.来那度胺的临床药代动力学与药效学
Clin Pharmacokinet. 2017 Feb;56(2):139-152. doi: 10.1007/s40262-016-0432-1.
7
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea.来那度胺在复发或难治性多发性骨髓瘤治疗中的应用:韩国专家建议
Blood Res. 2015 Mar;50(1):7-18. doi: 10.5045/br.2015.50.1.7. Epub 2015 Mar 24.
8
Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.来那度胺在治疗剂量和超治疗剂量下不会延长健康男性中全面 QTc 研究中的 QTc 间期。
Basic Clin Pharmacol Toxicol. 2013 Sep;113(3):179-86. doi: 10.1111/bcpt.12081. Epub 2013 Jun 20.
9
Pharmacokinetics and tissue disposition of lenalidomide in mice.来那度胺在小鼠体内的药代动力学和组织分布。
AAPS J. 2012 Dec;14(4):872-82. doi: 10.1208/s12248-012-9401-2. Epub 2012 Sep 7.
10
Clinical trial considerations on male contraception and collection of pregnancy information from female partners.男性避孕的临床试验考虑因素和从女性伴侣处收集妊娠信息。
J Transl Med. 2012 Jun 21;10:129. doi: 10.1186/1479-5876-10-129.